Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

4/1/2008 Telecon - Rotarix


DATE: April 1, 2008

CBER participants: Laraine Henchal, Jingyee Kou, Dale Horne, Lew Schrager, Douglas Pratt, Norman Baylor, Steve Rosenthal, Florence Houn, Luba Vujcic

GSK participants: Len Friedland, Tracey Lee, Benedicte T. Dupasquier, Brigette Chevart, Barbara Howe, Claire Khan, Michael Van der Wert, Donna Boyce

CBER and GSK discussed and finalized the indication for Rotarix. It was agreed to make the indication for prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) in infants and children. It was also agreed that the dating period for the product would be 24 months.

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 03/15/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English